IMMP - Immutep Limited

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.0500
0.0000 (0.00%)
At close: 04:00PM EDT
2.0100 -0.04 (-1.95%)
After hours: 07:11PM EDT
Stock chart is not supported by your current browser
Previous Close2.0500
Open2.0500
Bid2.0100 x 800
Ask2.0500 x 1100
Day's Range2.0300 - 2.1000
52 Week Range1.4700 - 3.9000
Volume200,948
Avg. Volume1,614,714
Market Cap183.094M
Beta (5Y Monthly)2.00
PE Ratio (TTM)N/A
EPS (TTM)-0.3400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.16
  • Simply Wall St.

    The 12% return this week takes Immutep's (ASX:IMM) shareholders three-year gains to 96%

    By buying an index fund, you can roughly match the market return with ease. But if you buy good businesses at...

  • GlobeNewswire

    Immutep to Participate at the Jefferies Healthcare Conference

    SYDNEY, AUSTRALIA, June 07, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces Marc Voigt, CEO of Immutep, will be presenting at the Jefferies Healthcare Conference being held on June 7-9, 2023 in New York City, NY. Event:Jefferies Healthcare ConferenceDate:Thursday, 8 June 2023 Time:10:00am – 10:25am (ET) A live webcast of

  • GlobeNewswire

    Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting

    Media Release Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression levels, and median Duration of Response not reached despite median follow up of 39 months in TACTI-002 Phase IIPromising efficacy in patients with a PD-L1 Combined Positive Score (CPS) of ≥1 with median Overall Survival of 12.6 months, a 12-month Overall Survival rate of 52.0%, and a response rate of 38.5%Patients with a PD-L1 CPS ≥20 achieved a median Overall Survival of 15.5 months, a 12-month

  • GlobeNewswire

    Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer

    Sydney, Australia, June 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited, an Australian company (ASX: IMM) (Nasdaq: IMMP) (Immutep or the Company), is pleased to announce the successful completion of an institutional placement (Placement) and the institutional component (Institutional Entitlement Offer) of its 1 for 7.6 pro rata accelerated non-renounceable entitlement offer (Entitlement Offer and, together with the Placement, the Offer) of new fully paid ordinary shares in Immutep (New Shares). Imm

  • GlobeNewswire

    Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study

    Media Release Appointment of Charles River Laboratories ("Charles River") to run Immutep’s preclinical toxicology study evaluating the safety and toxicity of IMP761Forms a key step prior to first-in-human trials for this first-in-class LAG-3 agonist antibody designed to treat the underlying cause of multiple autoimmune diseasesCharles River is a highly respected, global provider of drug discovery and non-clinical development solutions operating more than 110 sites across more than 20 countries S

  • GlobeNewswire

    Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting

    Media Release New data published from Part C of TACTI-002 Phase II Trial evaluating eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinomaDeep, durable responses seen across all PD-L1 subgroups with a 13.5% Complete Response rate and median Duration of Response not yet reached (minimum follow-up of 17 months)In the overall patient population, regardless of PD-L1 expression, a strong response rate of 29.7% and 12-month overall survival rate of 46.0% were

  • Zacks

    Immutep (IMMP) Up on Initial Data From Lung Cancer Study

    Immutep (IMMP) shares surge on encouraging initial data from a triple combination therapy study, INSIGHT-003, for non-small cell lung cancer.

  • GlobeNewswire

    Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

    Media Release SYDNEY, AUSTRALIA, May 25, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the first patient has been enrolled and safely dosed at a European clinical site for its integrated Phase II/III AIPAC-003 trial in metastatic breast cancer. AIPAC-003 is evaluating eftilagimod alpha (“efti”), Immutep’s soluble LAG-3

  • GlobeNewswire

    Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial

    Media Release Efti plus standard-of-care anti-PD-1 therapy and doublet chemotherapy in 1st line non-small cell lung cancer is well tolerated and continues to show promising initial signals of efficacyTriple combination therapy has achieved a 67% response rate and 91% disease control rate in metastatic 1st line non-small cell lung cancer patients (N=21) despite 81% of patients having low or negative PD-L1 expression SYDNEY, AUSTRALIA, May 24, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NA

  • Zacks

    Immutep (IMMP) Surges 65% on Upbeat Lung Cancer Study Data

    A mid-stage study data shows that Immutep's (IMMP) lead candidate as a combination therapy in first-line NSCLC achieved better-than-expected overall survival results.

  • GlobeNewswire

    Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

    Media Release Immuno-oncology combination of eftilagimod alpha (efti) and the leading anti-PD-1 therapy generates meaningful long-term survival in non-small cell lung cancer patients in Phase II TACTI-002 trialInitial median Overall Survival of 25 months in non-small cell lung cancer patients with >1% PD-L1 expression, a key area of focus for future development of eftiResult is above reported rates of anti-PD-1 monotherapy and various immune checkpoint inhibitor combinations with and without che

  • GlobeNewswire

    Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

    Media Release SYDNEY, AUSTRALIA, May 16, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received positive feedback from the US Food and Drug Administration (FDA), regarding the Company’s late-stage clinical development plans for its first-in-class soluble LAG-3 protein and MHC Class II agonist, eftilagimod alpha (

  • GlobeNewswire

    Immutep to Participate in the JMP Securities Life Sciences Conference

    Media Release SYDNEY, AUSTRALIA, May 09, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its management will present and be available for 1-on-1 meetings at the JMP Securities Life Sciences Conference, on Tuesday, May 16th, 2023. Presentation details: The JMP Securities Life Sciences Conference Location: New York Hilton M

  • GlobeNewswire

    Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma

    Media Release Webinar to take place on Tuesday, May 9, 2023, at 11:30 AM ET SYDNEY, AUSTRALIA, May 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces a Key Opinion Leader (KOL) event will be hosted by Ladenburg Thalmann & Co, Inc., on Tuesday, May 9, 2023, from 11:30 AM – 1:00 PM ET. The “Deep Dive into Efti Development in NSCLC and HNSCC Landscapes

  • GlobeNewswire

    Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®

    Media Release Investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate dual immuno-oncology (IO) combination of eftilagimod alpha and BAVENCIO® in metastatic urothelial cancerTrial builds on strategy to cost-efficiently increase target indications for IO-IO combination approaches utilizing eftilagimod alpha in areas of high unmet need SYDNEY, AUSTRALIA, May 01, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology

  • GlobeNewswire

    Immutep Quarterly Activities Report

    Media Release Initiation of integrated Phase II/III AIPAC-003 trial evaluating eftilagimod alpha (efti) and paclitaxel in HER2-neg/low metastatic breast cancer and triple-negative breast cancerPositive final data reported from patients with 2nd line non-small cell lung cancer refractory to anti-PD-(L)1 therapies, including Overall Survival rate of 39% at 21 monthsRandomised TACTI-003 Phase IIb trial has reached 75% enrolment subsequent to quarter end and top line results anticipated in H2 of CY2

  • GlobeNewswire

    Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting

    Media Release Final results from Part C of the Phase II TACTI-002 trial in 2nd line head and neck squamous cell carcinoma patients to be presented SYDNEY, AUSTRALIA, April 26, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces two abstracts have been selected for poster presentation at the upcoming 2023 American Society of C

  • GlobeNewswire

    Immutep Appoints Dr. Florian Vogl as Chief Medical Officer

    Media Release SYDNEY, AUSTRALIA, April 26, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces that Florian D. Vogl, M.D., Ph.D., MSc, has been appointed as Chief Medical Officer (CMO) with effect from 1 May 2023. Dr. Vogl brings to Immutep over a decade of experience in the biopharmaceutical industry with extensive clinical development expertise in the

  • GlobeNewswire

    Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting

    Media Release Soft tissue sarcoma, an orphan disease, represents a high unmet medical need with a poor prognosisFirst time efti will be studied in neoadjuvant, non-metastatic cancer settingNovel triple combination of efti with radiotherapy and anti-PD-1 therapy has potential to generate a robust anti-tumour immune response SYDNEY, AUSTRALIA, April 17, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing

  • GlobeNewswire

    Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023

    Media Release Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate at 21 months, which compare favourably to typical 6-9 months mOS and a 10-15% OS rate for standard-of-care chemotherapy83% of patients studied for Tumour Growth Kinetics showed deceleration of tumour growth or shrinkage of tumours, previously increasing under PD-(L)1 monotherapy or in combination with chemotherapyORR of 8.3%, DCR of 33.3%, and 6-month PFS rate of 25% in all-comer PD-L1 patient population, with mos

  • GlobeNewswire

    Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer

    Media Release Expanding INSIGHT-003 trial evaluating efti with standard-of-care combination of anti-PD-1 therapy and chemotherapy to 50 patientsExpansion based on safety and strong initial efficacy resultsData updates expected throughout CY2023 and cost-efficient approach through investigator-initiated trial will further inform options related to 1L NSCLC developmentClinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and I

  • GlobeNewswire

    Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023

    Media Release 2nd line NSCLC patients refractory to anti-PD-(L)1 treatment have few therapeutic options, and the addition of efti to pembrolizumab may help these patients by reverting anti-PD-(L)1 therapy resistance83% of patients that were studied for Tumor Growth Kinetics showed deceleration (50%) in tumour growth or shrinkage (33%) of target lesionsOverall Response Rate (ORR) of 8.3% and Disease Control Rate (DCR) of 33% and responses were confirmed and durable with patients on study 19+ mont

  • GlobeNewswire

    Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer

    Media Release Integrated Phase II/III trial design incorporates feedback from the FDA and EMA and will help inform a BLA and MAAHR+/HER2-neg/low metastatic breast cancer (MBC) patient population has been expanded to include triple-negative breast cancer, which together account for ~78% of breast cancer casesApproval for study start received in US and IRB approval in Spain, with more countries to follow shortlyFirst patient expected to be enrolled in early Q2 CY2023As a first-in-class APC activat

  • Simply Wall St.

    Immutep First Half 2023 Earnings: AU$0.024 loss per share (vs AU$0.019 loss in 1H 2022)

    Immutep ( ASX:IMM ) First Half 2023 Results Key Financial Results Net loss: AU$20.6m (loss widened by 27% from 1H...

  • GlobeNewswire

    Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

    Media Release 20 patients with 1st line non-small cell lung cancer (1L NSCLC) now enrolled in the first triple combination therapy study of efti with standard-of-care combination of anti-PD-1 therapy and chemotherapyPromising initial efficacy results showing a 72.7% response rate and 90.9% disease control rate reported at SITC 2022Additional data is expected throughout calendar year 2023 and will further inform our next steps in 1L NSCLC SYDNEY, AUSTRALIA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Immut